Content |
Owners
History
2020
Mikhail Murashko's proposal to give Immunotechnology the status of a single supplier of vaccines for COVID-19 at public procurement
On December 1, 2020, it became known that the structure of Sber Immunotechnology could become a single supplier of vaccines for the prevention of COVID-19. Representatives of Sber, Immunotechnology and the government declined to comment.
With the offer to allocate Immunotekhnologiya with the status of the uniform supplier of vaccines for prevention of COVID-19 on state procurements in November the minister zdravookhraneniyamikhait Murashko addressed the prime minister Mikhail Mishustin. Vedomosti got acquainted with a copy of the letter. It states that the company has "all the necessary capabilities and competencies to optimally meet the needs of government customers."
It also says that the Ministry of Health has already developed a draft government order to give the company the status of a single supplier. In the letter, Murashko asks Mishustin to instruct the Ministry of Finance, the Ministry of Industry and Trade and the Federal Antimonopoly Service (FAS) to coordinate the project "as soon as possible." The representative of the Ministry of Finance confirmed that the draft government order was submitted to the ministry for consideration. The Ministry of Finance has already sent its comments to the government, the Vedomosti interlocutor added, but did not specify which ones. Representatives of the Ministry of Industry and Trade and the FAS did not respond to requests.
According to SPARK-Interfax, Immunotechnology LLC was registered in May, it is 100% owned by Digital Assets, Sbera's daughter. It is headed by Dmitry Efimov, former general director of the Russian JSC Nizhpharm"," the Russian the structures the German of the pharmaceutical company Stada. The main activity of Immunotechnology is indicated by wholesale trade pharmaceutical products.
Experts doubt that the government will choose Immunotechnology as a single supplier.
In addition, Immunotechnology does not have its own production and logistics facilities, says Nikolai Bespalov, development director at RNC Pharma. Therefore, they will have to attract third-party distributors who will be able to ensure the storage and supply of vaccines at the necessary temperature.
According to him, it was originally planned that Immunotechnologies will search for sites for the production of the Russian Sputnik V vaccine and its promotion both on the Russian and international markets, and not deliveries to the regions[1].
Production of COVID-19 vaccine
On August 21, 2020, German Gref, Chairman of the Board of Sberbank, announced that a subsidiary of Immunotechnology LLC was created to produce a vaccine for COVID-19 coronavirus.
 | It was created just for the creation of this vaccine, as a project office for the creation of this vaccine. This is a subsidiary, Gref told reporters following the results of the supervisory board. |  |
He clarified that Immunotechnology as a project office helps the Ministry of Health of the Russian Federation and institutions to develop and transfer technologies.
Sberbank's subsidiary will not develop a new type of coronavirus vaccine, but focus on its production. Earlier, German Gref said that at the request of the government, the state bank is working "very closely" together with the Ministry of Health to support the organization of vaccine production.
| | We see that without a vaccine it is so easy to deal with this problem. Therefore, we decided that we would spend our personal money and corporation money on this, "he said. | |
Immunotechnology will produce the Gam-KOVID-Vak vaccine (market name Sputnik-V) from the N.F. Gamalei National Research Center for Epidemiology and Microbiology (NITSEM), which filed documents on August 21, 2020 to obtain permission for the third stage of clinical trials of the drug. The start of mass production of the vaccine is scheduled for September 2020. In August, deliveries of small batches began, which will be distributed by the Ministry of Health.
The position of Deputy General Director of Immunotechnology LLC was taken by Ivan Glushkov, who previously headed the STADA foreign relations department in Russia. Dmitry Efimov, General Director of Immunotechnology LLC, worked at STADA with Glushkov for more than 10 years.[2]
Creation of the company
In mid-May 2020, it became known that Sberbank created a new company - Immunotechnology LLC - with an authorized capital of 50 million rubles. It was headed by Dmitry Efimov, former general director of Nizhfarm and senior vice president of Stada CIS. The company was registered on May 15.
According to TASS"" with reference to the database "," SPARK-Interfax the main activity of Immunotechnology is the wholesale trade in pharmaceutical products, the production of pharmaceutical substances and medicines, scientific research and development in the field of biotechnology.
According to Farmvestnik, the new company will scale up the production of a vaccine for coronavirus, COVID-19 which it is developing. The National Research Center (NIC) for Epidemiology and Microbiology named after Academician N.F. Gamalei organization hopes that the vaccine will be registered and begin to be produced by August 2020 , said Director of the Research Center Alexander Ginzburg on May 16.
The development strategy of Sberbank for 2020 did not provide for the creation of a pharmaceutical company. For the bank, Immunotechnology LLC is not a business project, but the organization's contribution to the fight against the pandemic, the source explained.
Earlier in May 2020, Sberbank sent a letter to employees with a proposal to become volunteers in testing a vaccine against coronavirus. Prior to this, the bank decided to allocate more than 3 billion rubles to combat the coronavirus pandemic. The funds were collected, including by bank employees - in particular, top managers decided to direct their salaries for April for these purposes.
Sberbank also announced the launch of the charity project "Stop coronavirus together" and doubling the contribution of bank customers to this program. It was noted that the funds will be used to support Russian projects to create a vaccine and medicines designed to combat COVID-19.[3]
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |